Skip to main content
Have a personal or library account? Click to login
Comparative Efficacy of Different Biologic Agents on Radiographic Progression in Patients with Rheumatoid Arthritis: A Network Meta-Analysis Cover

Comparative Efficacy of Different Biologic Agents on Radiographic Progression in Patients with Rheumatoid Arthritis: A Network Meta-Analysis

By: ,  ,   and    
Open Access
|Nov 2026
Read online

References

  1. Asano T, Ishii Y, Tsuchiya H et al. (2024) Efficacy of golimumab in rheumatoid arthritis patients at high risk of a poor prognosis: Post hoc analysis of GO-FORTH study using cluster analysis. Mod Rheumatol 34:1125–1134. https://doi.org/10.1093/mr/roae037
  2. Bernabela L, Bermas B (2024) Immune checkpoint inhibitor associated rheumatoid arthritis. Curr Rheumatol Rep 27:3. https://doi.org/10.1007/s11926-024-01173-6
  3. Blanco FJ, Möricke R, Dokoupilova E et al. (2017) Secukinumab in active rheumatoid arthritis: A Phase III randomized, double-blind, active comparator- and placebo-controlled study. Arthritis Rheumatol 69:1144–1153. https://doi.org/10.1002/art.40070
  4. Breedveld FC, Emery P, Keystone E et al. (2004) Infliximab in active early rheumatoid arthritis. Ann Rheum Dis 63:149–155. https://doi.org/10.1136/ard.2003.013961
  5. Breedveld FC, Jones HE, Peifer K et al. (2018) A pilot dose-finding study of etanercept in rheumatoid arthritis. Clin Transl Sci 11:38–45. https://doi.org/10.1111/cts.12502
  6. Breedveld FC, Weisman MH, Kavanaugh AF et al. (2006) The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37. https://doi.org/10.1002/art.21519
  7. Buttgereit F, Aelion J, Rojkovich B et al. (2023) Efficacy and safety of ABBV-3373, a novel anti-tumor necrosis factor glucocorticoid receptor modulator antibody-drug conjugate, in adults with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: A randomized, double-blind, active-controlled proof-of-concept Phase IIa trial. Arthritis Rheumatol 75:879–889. https://doi.org/10.1002/art.42415
  8. Cohen SB, Emery P, Greenwald MW et al. (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793–2806. https://doi.org/10.1002/art.22025
  9. Cope AP, Jasenecova M, Vasconcelos JC et al. (2024) Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): A randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial. Lancet 403:838–849. https://doi.org/10.1016/S0140-6736(23)02649-1
  10. Cush JJ (2022) Rheumatoid arthritis: Early diagnosis and treatment. Rheum Dis Clin North Am 48:537–547. https://doi.org/10.1016/j.rdc.2022.02.010
  11. Deakin CT, De Stavola BL, Littlejohn G et al. (2023) Comparative effectiveness of adalimumab vs tofacitinib in patients with rheumatoid arthritis in Australia. JAMA Netw Open 6:e2320851. https://doi.org/10.1001/jamanetworkopen.2023.20851
  12. Dokoupilová E, Aelion J, Takeuchi T et al. (2018) Secukinumab after anti-tumour necrosis factor-α therapy: A phase III study in active rheumatoid arthritis. Scand J Rheumatol 47:276–281. https://doi.org/10.1080/03009742.2017.1390605
  13. Emery P, Fleischmann RM, Hsia EC et al. (2014) Efficacy of golimumab plus methotrexate in methotrexate-naïve patients with severe active rheumatoid arthritis. Clin Rheumatol 33:1239–1246. https://doi.org/10.1007/s10067-014-2731-y
  14. Fleischmann R, Mysler E, Hall S et al. (2017) Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): A phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 390:457–468. https://doi.org/10.1016/S0140-6736(17)31618-5
  15. Genovese MC, Greenwald M, Cho CS et al. (2014) A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors. Arthritis Rheumatol 66:1693–1704. https://doi.org/10.1002/art.38617
  16. Genovese MC, Kaine JL, Lowenstein MB et al. (2008) Ocrelizumab, a humanized anti-CD20 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I/II randomized, blinded, placebo-controlled, dose-ranging study. Arthritis Rheum 58:2652–2661. https://doi.org/10.1002/art.23732
  17. Giles JT, Sattar N, Gabriel S et al. (2020) Cardiovascular safety of tocilizumab versus etanercept in rheumatoid arthritis: A randomized controlled trial. Arthritis Rheumatol 72:31–40. https://doi.org/10.1002/art.4109
  18. He B, Li Y, Luo WW et al. (2022) The risk of adverse effects of TNF-α inhibitors in patients with rheumatoid arthritis: A network meta-analysis. Front Immunol 13:814429. https://doi.org/10.3389/fimmu.2022.814429
  19. Hetland ML, Haavardsholm EA, Rudin A et al. (2020) Active conventional treatment and three different biological treatments in early rheumatoid arthritis: Phase IV investigator initiated, randomised, observer blinded clinical trial. BMJ 371:m4328. https://doi.org/10.1136/bmj.m4328
  20. Humby F, Durez P, Buch MH et al. (2021) Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial. Lancet 397:305–317. https://doi.org/10.1016/S0140-6736(20)32341-2
  21. Jairath V, Felquer MLA, Cho RJ (2024) IL-23 inhibition for chronic inflammatory disease. Lancet 404:1679–1692. https://doi.org/10.1016/S0140-6736(24)01750-1
  22. Jang S, Kwon E-J, Lee JJ (2022) Rheumatoid arthritis: Pathogenic roles of diverse immune cells. Int J Mol Sci 23:905. https://doi.org/10.3390/ijms23020905
  23. Kerschbaumer A, Sepriano A, Bergstra SA et al. (2023) Efficacy of synthetic and biological DMARDs: A systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 82:95–106. https://doi.org/10.1136/ard-2022-223365
  24. Li KH, Kaker M, Lau J et al. (2024) The landscape of real-world evidence of rituximab utilization and clinical outcomes in patients with cancer, rheumatoid arthritis, and multiple sclerosis: A scoping review. J Manag Care Spec Pharm 30:480–489. https://doi.org/10.18553/jmcp.2024.30.5.480
  25. Liu T, Wang L, Zhang X et al. (2025) Tocilizumab monotherapy or combined with methotrexate for rheumatoid arthritis: A randomized clinical trial. JAMA Netw Open 8:e2511095. https://doi.org/10.1001/jamanetworkopen.2025.11095
  26. Mohanakrishnan R, Beier S, Deodhar A (2022) IL-23 inhibition for the treatment of psoriatic arthritis. Expert Opin Biol Ther 22:59–65. https://doi.org/10.1080/14712598.2021.1938538
  27. Nair S, Singh Kahlon S, Sikandar R et al. (2022) Tumor necrosis factor-alpha inhibitors and cardiovascular risk in rheumatoid arthritis: A systematic review. Cureus 14:e31938. https://doi.org/10.7759/cureus.26430
  28. Rech J, Tascilar K, Hagen M et al. (2024) Abatacept inhibits inflammation and onset of rheumatoid arthritis in individuals at high risk (ARIAA): A randomised, international, multicentre, double-blind, placebo-controlled trial. Lancet 403:850–859. https://doi.org/10.1016/S0140-6736(23)02650-8
  29. Rigby W, Tony HP, Oelke K et al. (2012) Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 64:350–359. https://doi.org/10.1002/art.33317
  30. Rivellese F, Nerviani A, Giorli G et al. (2023) Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): Two parallel, open-label, biopsy-driven, randomised trials. Lancet Rheumatol 5:e648–e659. https://doi.org/10.1016/S2665-9913(23)00241-2
  31. Rubbert-Roth A, Enejosa J, Pangan AL et al. (2020) Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med 383:1511–1521. https://doi.org/10.1056/NEJMoa2008250
  32. Scherer HU, van der Woude D, Toes RE (2022) From risk to chronicity: Evolution of autoreactive B cell and antibody responses in rheumatoid arthritis. Nat Rev Rheumatol 18:371–383. https://doi.org/10.1038/s41584-022-00786-4
  33. Smolen JS, Agarwal SK, Ilivanova E et al. (2017) A randomised phase II study evaluating the efficacy and safety of subcutaneously administered ustekinumab and guselkumab in patients with active rheumatoid arthritis despite treatment with methotrexate. Ann Rheum Dis 76:831–839. https://doi.org/10.1136/annrheumdis-2016-209831
  34. Smolen JS, Edwards CJ, Konzett V et al. (2026) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biologic disease-modifying antirheumatic drugs: 2025 update. Ann Rheum Dis 85:991–1009. https://doi.org/10.1016/j.ard.2026.01.023
  35. Suto T, Okamura K, Sakane H et al. (2023) The impact of bDMARDs on postoperative complications in patients with rheumatoid arthritis: A systematic review and meta-analysis. Medicine 102:e36132. https://doi.org/10.1097/MD.0000000000036132
  36. Takanashi S, Kondo Y, Saito S et al. (2023) Effectiveness and safety of rituximab in special types of rheumatoid arthritis. Intl J Rheum Dis 26:2240–2247. https://doi.org/10.1111/1756-185X.14920
  37. Tak PP, Mease PJ, Genovese MC et al. (2012) Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: Results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial. Arthritis Rheum 64:360–370. https://doi.org/10.1002/art.33353
  38. Taylor PC, Weinblatt ME, McInnes IB et al. (2023) Anti-GM-CSF otilimab versus sarilumab or placebo in patients with rheumatoid arthritis and inadequate response to targeted therapies: A phase III randomised trial (contRAst 3). Ann Rheum Dis 82:1527–1537. https://doi.org/10.1136/ard-2023-224449
  39. Toghi M, Bitarafan S, Ghafouri-Fard S (2023) Pathogenic Th17 cells in autoimmunity with regard to rheumatoid arthritis. Pathol Res Pract 250:154818. https://doi.org/10.1016/j.prp.2023.154818
  40. Uke P, Maharaj A, Adebajo A (2025) A review on the epidemiology of rheumatoid arthritis: An update and trends from current literature. Best Pract Res Clin Rheumatol 39:102036. https://doi.org/10.1016/j.berh.2025.102036
  41. Venetsanopoulou AI, Alamanos Y, Voulgari PV et al. (2022) Epidemiology of rheumatoid arthritis: Genetic and environmental influences. Expert Rev Clin Immunol 18:923–931. https://doi.org/10.1080/1744666X.2022.2106970
  42. Weinblatt ME, Keystone EC, Furst DE et al. (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trial. Arthritis Rheum 48:35–45. https://doi.org/10.1002/art.10697
  43. Weinblatt ME, Taylor PC, McInnes IB et al. (2025) Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: Long-term extension of three phase 3 randomised trials (contRAst X). BMJ Open 15:e088869. https://doi.org/10.1136/bmjopen-2024-088869
  44. Wu D, Luo Y, Li T et al. (2022) Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment. Front Immunol 13:1051082. https://doi.org/10.3389/fimmu.2022.1051082
  45. Yoshimura Y, Yamanouchi M, Mizuno H et al. (2024) Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease. Ann Rheum Dis 83:1278–1287. https://doi.org/10.1136/ard-2024-225914
Language: English
Submitted on: May 6, 2026
Accepted on: Sep 8, 2026
Published on: Nov 10, 2026
Published by: Hirszfeld Institute of Immunology and Experimental Therapy
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year

© 2026 Di Liu, Na Yuan, Guimei Yu, Daqing Nie, published by Hirszfeld Institute of Immunology and Experimental Therapy
This work is licensed under the Creative Commons Attribution 4.0 License.